Gatifloxacin Induces S and G2-Phase Cell Cycle Arrest in Pancreatic Cancer Cells via p21/p27/p53

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Yadav, Vikas ^a,b   Sultana, Sarwat ^b   Yadav, Jyoti ^a   Saini, Neeru ^a  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^b HAMDARD UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GATIFLOXACIN; GEMCITABINE; PROTEIN KINASE B; PROTEIN P53; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL NUCLEUS; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; HUMAN; HUMAN CELL; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; UPREGULATION;

ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FLOW CYTOMETRY; FLUOROQUINOLONES; G2 PHASE; HUMANS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; S PHASE; S-PHASE KINASE-ASSOCIATED PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

AGOUTI PACA;

EID: 84868109829     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047796     Document Type: Article

References (54)

1. Lillemoe KD, (1995) Current management of pancreatic carcinoma. Ann Surg 221: 133-148.
2. Duffy JP, Eibl G, Reber HA, Hines OJ, (2003) Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol.Cancer 2: 12.
3. Apte MV, Park S, Phillips PA, Santucci N, Goldstein D, et al. (2004) Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas 29: 179-187.
4. Riall TS, Cameron JL, Lillemoe KD, Winter JM, Campbell KA, et al. (2006) Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery 140: 764-772.
5. Bao PQ, Ramanathan RK, Krasinkas A, Bahary N, Lembersky BC, et al. (2011) III, Erratum to: Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer Ann Surg Oncol.
6. Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, et al. (1994) Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg. 81: 882-885.
7. Aranha O, Wood DP Jr, Sarkar FH, (2000) Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin.Cancer Res. 6: 891-900.
8. Fabian I, Reuveni D, Levitov A, Halperin D, Priel E, et al. (2006) Moxifloxacin enhances antiproliferative and apoptotic effects of etoposide but inhibits its proinflammatory effects in THP-1 and Jurkat cells. Br J Cancer 95: 1038-1046.
9. Herold C, Ocker M, Ganslmayer M, Gerauer H, Hahn EG, et al. (2002) Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer 86: 443-448.
10. Jun YT, Kim HJ, Song MJ, Lim JH, Lee DG, et al. (2003) In vitro effects of ciprofloxacin and roxithromycin on apoptosis of jurkat T lymphocytes. Antimicrob Agents Chemother. 47: 1161-1164.
11. Drlica K, (1999) Mechanism of fluoroquinolone action. Curr Opin Microbiol. 2: 504-508.
12. Khodursky AB, ZechiedrichEL, Cozzarelli NR, (1995) Topoisomerase IV is a target of quinolones in Escherichia coli. Proc Natl Acad Sci U.S.A 92: 11801-11805.
13. Shen LL, Baranowski J, Pernet AG, (1989) Mechanism of inhibition of DNA gyrase by quinolone antibacterials: specificity and cooperativity of drug binding to DNA. Biochemistry 28: 3879-3885.
14. Khan AA, Slifer TR, Araujo FG, Remington JS, (2001) Activity of gatifloxacin alone or in combination with pyrimethamine or gamma interferon against Toxoplasma gondii. Antimicrob Agents Chemother. 45: 48-51.
15. Maeda S, Tamaki M, Kubota Y, Nguyen PB, Yasuda M, et al. (2007) Treatment of men with urethritis negative for Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum. Int J Urol. 14: 422-425.
16. Piercy T, Steward J, Lever MS, Brooks TJ, (2005) In vivo efficacy of fluoroquinolones against systemic tularaemia infection in mice. J Antimicrob Chemother. 56: 1069-1073.
17. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, et al. (2008) A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int.J.Tuberc.Lung Dis. 12: 128-138.
18. Takeyama K, Mitsuzawa H, Nishitani C, Shimizu T, Sano H, et al. (2007) The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. Antimicrob.Agents Chemother. 51: 162-168.
19. Adam U, Herms S, Werner U, Strubelt H, Makowiec F, et al. (2001) The penetration of ciprofloxacin into human pancreatic and peripancreatic necroses in acute necrotizing pancreatitis. Infection 29: 326-331.
20. Nicolas FJ, Hill CS, (2003) Attenuation of the TGF-beta-Smad signaling pathway in pancreatic tumor cells confers resistance to TGF-beta-induced growth arrest. Oncogene 22: 3698-3711.
21. Bourikas LA, Kolios G, Valatas V, Notas G, Drygiannakis I, et al. (2009) Ciprofloxacin decreases survival in HT-29 cells via the induction of TGF-beta1 secretion and enhances the anti-proliferative effect of 5-fluorouracil. Br J Pharmacol. 157: 362-370.
22. Truty MJ, Urrutia R, (2007) Basics of TGF-beta and pancreatic cancer. Pancreatology. 7: 423-435.
23. Kretschmer A, Moepert K, Dames S, Sternberger M, Kaufmann J, et al. (2003) Differential regulation of TGF-beta signaling through Smad2, Smad3 and Smad4. Oncogene 22: 6748-6763.
24. Heldin CH, Miyazono K, Ten DP, (1997) TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390: 465-471.
25. Lagna G, Hata A, Hemmati-Brivanlou A, Massague J, (1996) Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways. Nature 383: 832-836.
26. Liu F, Pouponnot C, Massague J (1997) Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes. Genes Dev. 11 (1997) 3157-3167.
27. Moustakas A, Kardassis D, (1998) Regulation of the human p21/WAF1/Cip1 promoter in hepatic cells by functional interactions between Sp1 and Smad family members. Proc Natl Acad Sci U.S.A 95: 6733-6738.
28. Chu IM, Hengst L, Slingerland JM, (2008) The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 8: 253-267.
29. Reed SI, (2003) Ratchets and clocks: the cell cycle, ubiquitylation and protein turnover. Nat. Rev. Mol. Cell. Biol. 11: 855-864.
30. Oren M, (2003) Decision making by p53: life, death and cancer. Cell Death Differ. 10: 431-442.
31. Gottlieb TM, Leal JF, Seger R, Taya Y, Oren M, (2002) Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene 21: 1299-1303.
32. Barton CM, Staddon SL, Hughes CM, Hall PA, Sullivan CO, et al. (1991) Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 64: 1076-1082.
33. Malumbres M, Barbacid M, (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9: 153-166.
34. Vermeulen K, Van Bockstaele DR, Berneman ZN, (2003) The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 36: 131-149.
35. Heinemann V, Wilke H, Mergenthaler HG, Clemens M, Konig H, et al. (2000) Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 11: 1399-1403.
36. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, et al. (2002) Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 94: 902-910.
37. Kim MP, Gallick GE, (2008) Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res. 14: 1284-1285.
38. Aranha O, Grignon R, Fernandes N, McDonnell TJ, Wood DP Jr, et al. (2003) Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis. Int J Oncol. 22: 787-794.
39. Mondal ER, Das SK, Mukherjee P, (2004) Comparative evaluation of antiproliferative activity and induction of apoptosis by some fluoroquinolones with a human non-small cell lung cancer cell line in culture. Asian Pac J Cancer Prev. 5: 196-204.
40. Reuveni D, Halperin D, Fabian I, Tsarfaty G, Askenasy N, et al. (2010) Moxifloxacin increases anti-tumor and anti-angiogenic activity of irinotecan in human xenograft tumors. Biochem Pharmacol. 79: 1100-1107.
41. Reuveni D, Halperin D, Shalit I, Priel E, Fabian I, (2010) Moxifloxacin enhances etoposide-induced cytotoxic, apoptotic and anti-topoisomerase II effects in a human colon carcinoma cell line. Int J Oncol. 37: 463-471.
42. Jin YH, Choi J, Shin S, Lee KY, Park JH, et al. (2003) Panaxadiol selectively inhibits cyclin A-associated Cdk2 activity by elevating p21WAF1/CIP1 protein levels in mammalian cells. Carcinogenesis 24: 1767-1772.
43. Grana X, Reddy EP, (1995) Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11: 211-219.
44. Miralles F, Battelino T, Czernichow P, Scharfmann R, (1998) TGF-beta plays a key role in morphogenesis of the pancreatic islets of Langerhans by controlling the activity of the matrix metalloproteinase MMP-2. J Cell Biol. 143: 827-836.
45. Hahm KB, Im YH, Lee C, Parks WT, Bang YJ, et al. (2000) Loss of TGF-beta signaling contributes to autoimmune pancreatitis. J Clin Invest 105: 1057-1065.
46. Wagner M, Kleeff J, Lopez ME, Bockman I, Massaque J, et al. (1998) Transfection of the type I TGF-beta receptor restores TGF-beta responsiveness in pancreatic cancer. Int J Cancer 78: 255-260.
47. Pardali K, Kurisaki A, Moren A, Ten DP, Kardassis D, et al. (2000) Role of Smad proteins and transcription factor Sp1 in p21(Waf1/Cip1) regulation by transforming growth factor-beta. J Biol Chem. 275: 29244-29256.
48. Johnson DG, Walker CL, (1999) Cyclins and cell cycle checkpoints. Annu.Rev.Pharmacol.Toxicol. 39: 295-312.
49. Fahy BN, Schlieman M, Virudachalam S, Bold RJ, (2003) AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. Br J Cancer 89: 391-397.
50. Goel A, Prasad AK, Parmar VS, Ghosh B, Saini N, (2007) 7,8-Dihydroxy-4-methylcoumarin induces apoptosis of human lung adenocarcinoma cells by ROS-independent mitochondrial pathway through partial inhibition of ERK/MAPK signaling. FEBS Lett. 581: 2447-2454.
51. Goel A, Prasad AK, Parmar VS, Ghosh B, Saini N, (2009) Apoptogenic effect of 7,8-diacetoxy-4-methylcoumarin and 7,8-diacetoxy-4-methylthiocoumarin in human lung adenocarcinoma cell line: role of NF-kappaB, Akt, ROS and MAP kinase pathway. Chem.Biol.Interact. 179: 363-374.
52. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29 e45.
53. Chhabra R, Adlakha YK, Hariharan M, Scaria V, et al. (2009) Upregulation of miR-23a-27a-24-2 cluster induces caspase-dependent and-independent apoptosis in human embryonic kidney cells. PLoS One. 4: e5848.
54. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, et al. (1998) Requirment for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-501.